Please use this identifier to cite or link to this item:
Title: mTOR inhibition prevents coronary artery remodeling in a murine model of Kawasaki disease.
Austin Authors: Stock, Angus T;Parsons, Sarah;D'Silva, Damian B;Hansen, Jacinta A;Sharma, Varun J;James, Fiona L ;Starkey, Graham M ;D'Costa, Rohit;Gordon, Claire L ;Wicks, Ian P
Affiliation: Cardiac Surgery
Victorian Institute of Forensic Medicine, Melbourne, 3006, Australia
Liver & Intestinal Transplant Unit, Austin Health, Melbourne, 3084, Australia
Surgery (University of Melbourne)
DonateLife Victoria, Carlton, 3053, Australia
Department of Intensive Care Medicine, Melbourne Health, Melbourne, 3084, Australia
Infectious Diseases
Department of Microbiology and Immunology, The University of Melbourne, The Peter Doherty Institute for Infection and Immunity, Melbourne, 3052, Australia
North Eastern Public Health Unit, Austin Health, Melbourne, 3084, Australia
Rheumatology Unit, The Royal Melbourne Hospital, 3050, Australia
University of Melbourne, Department of Medical Biology, 3052, Australia
Department of Forensic Medicine, Monash University, Melbourne, 3006, Australia
Issue Date: 3-Sep-2022
Date: 2022
Publication information: Arthritis & Rheumatology (Hoboken, N.J.) 2023; 75(2):305-317
Abstract: Remodeling of the coronary arteries is a common feature in severe cases of Kawasaki Disease (KD). This pathology is driven by the dysregulated proliferation of vascular fibroblasts which can lead to coronary artery aneurysms, stenosis and myocardial ischemia. We therefore investigated whether inhibiting fibroblast proliferation might be an effective therapeutic strategy to prevent coronary artery remodeling in KD. We used a murine model of KD (induced by the injection of the Candida albicans water soluble complex; CAWS) and analysis of patient samples to evaluate potential anti-fibrotic therapies for KD. We identified the mTOR pathway as a potential therapeutic target in KD. The mTOR inhibitor rapamycin potently inhibited cardiac fibroblast proliferation in vitro, and vascular fibroblasts upregulated mTOR kinase signaling in vivo during the CAWS mouse model of KD. We evaluated the in vivo efficacy of mTOR inhibition and found that the therapeutic administration of rapamycin reduced vascular fibrosis and intimal hyperplasia of the coronary arteries in CAWS injected mice. Furthermore, the analysis of cardiac tissue from KD fatalities revealed that vascular fibroblasts localizing with inflamed coronary arteries upregulate mTOR signaling, confirming that the mTOR pathway is active in human KD. Our findings demonstrate that mTOR signaling contributes to coronary artery remodeling in KD, and that targeting this pathway offers a potential therapeutic strategy to prevent or restrict this pathology in high-risk KD patients. This article is protected by copyright. All rights reserved.
DOI: 10.1002/art.42340
ORCID: 0000-0002-3386-1857
Journal: Arthritis & Rheumatology (Hoboken, N.J.)
PubMed URL: 36057112
Type: Journal Article
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on May 17, 2024

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.